Kontrol Technologies Expands BioCloud Technology into Japan

Rhea-AI Summary

Kontrol Technologies Corp. (OTCQB:KNRLF) is expanding its BioCloud technology into Japan through a partnership with a seasoned trading company specializing in HVAC systems. This collaboration aims to finalize a distribution agreement by February 2022, enhancing Kontrol's global footprint. Furthermore, the company provided an update on ongoing performance testing of BioCloud technology, emphasizing its real-time detection capabilities for airborne viruses, including SARS-CoV-2. However, the company clarifies that its product is not a medical device and does not claim to eliminate COVID-19.

Positive

• Expansion into Japan through a partnership with a trading company experienced in HVAC systems.
• Anticipation of a distribution agreement by February 2022, which could strengthen market presence.
• Ongoing performance testing of BioCloud technology demonstrates commitment to innovation in air quality monitoring.

Negative

• The company does not make claims regarding the elimination of COVID-19, indicating limitations in BioCloud's capabilities.

Provides Additional Performance Testing Update

TORONTO--(BUSINESS WIRE)-- Kontrol Technologies Corp. (NEO:KNR) (OTCQB:KNRLF) (FSE:1K8) (“Kontrol” or the “Company”), a leader in smart buildings and cities through IoT, Cloud and SaaS technology, is expanding its BioCloud technology global footprint with a Japan-based trading company.

“BioCloud continues to garner international interest given the growing, ubiquitous need for creating safer spaces and monitoring of heating, cooling and ventilation systems (HVAC) in real-time,” said Paul Ghezzi, CEO of Kontrol Technologies.

Kontrol is partnering with a well-established trading company in Japan that has a 60-year history of large-scale deployment of HVAC and air quality systems. Kontrol and the trading company are negotiating a distribution agreement and are currently working together for technology demonstrations in the region. A distribution agreement is anticipated to be completed in February 2022. The trading company will not be named for industry competitive purposes.

Additional Testing Update

Following the press release dated January 5^th, 2022, Kontrol has provided an update on additional performance testing of the BioCloud technology at a level two lab. The additional testing was performed in conjunction with new interface features which were designed to be utilized and shared by researchers and applicable customers to validate the presence of the SARS-CoV-2 virus, and the level of detection response to better determine the safety of an area, and effectiveness of current site safety protocols. A copy of the updated research is available at https://kontrolbiocloud.com/summarytesting0113

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).

About Kontrol BioCloud^TM

Kontrol BioCloud (“BioCloud”) is an operating subsidiary of Canadian public company Kontrol Technologies. The BioCloud technology is a real-time analyzer designed to detect airborne viruses and pathogens. BioCloud is an air quality technology and not a medical device. BioCloud has been designed to operate as a safe space technology by sampling the air quality continuously. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and a silent notification system is created. Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com

Kontrol Technologies Corp.

Kontrol Technologies Corp. is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol provides a combination of software, hardware, and service solutions to its customers to improve energy management, air quality and continuous emission monitoring.

Additional information about Kontrol Technologies Corp. can be found on its website at www.kontrolcorp.com and by reviewing its profile on SEDAR at www.sedar.com.

Facebook | Twitter | LinkedIn

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions, and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Where Kontrol expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all; that those technologies will not prove as effective as expected; those customers and potential customers will not be as accepting of the Company's product and service offering as expected; and government and regulatory factors impacting the energy conservation industry. Kontrol BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220114005274/en/

Kontrol Technologies Corp.

Paul Ghezzi

CEO

info@kontrolcorp.com

180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8

Tel: (905) 766.0400

Investor Relations:

Brooks Hamilton

MZ Group – MZ North America

KNRLF@mzgroup.us

Tel: +1 (949) 546.6326

Source: Kontrol Technologies Corp.

FAQ

What is the recent news about Kontrol Technologies Corp. (KNRLF)?

Kontrol Technologies Corp. is expanding its BioCloud technology into Japan through a partnership with a trading company and is negotiating a distribution agreement, expected to be finalized by February 2022.

What does BioCloud technology do for Kontrol Technologies Corp. (KNRLF)?

BioCloud technology is designed to monitor air quality and detect airborne viruses, including SARS-CoV-2, enhancing safety in monitored spaces.

When is Kontrol Technologies Corp. (KNRLF) expecting to finalize its distribution agreement in Japan?

The distribution agreement with the Japan-based trading company is anticipated to be completed by February 2022.

What are the limitations of BioCloud technology as reported by Kontrol Technologies Corp. (KNRLF)?

Kontrol Technologies does not claim that BioCloud technology can eliminate or cure COVID-19, and it clarifies that the product is not a medical device.